CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Selective Cell Death Mediated by Small Conditional RNAs Here, researchers describe small conditional RNAs that undergo hybridization chain reactions to induce cell death via an innate immune response if and only if a cognate mRNA cancer marker is detected within a cell. [Proc Natl Acad Sci USA] Epithelial Hic-5/ARA55 Expression Contributes to Prostate Tumorigenesis and Castrate Responsiveness To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, researchers compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. [Oncogene] Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists To better characterize expression of tumoral luteinizing hormone-releasing hormone (LH-RH) receptors, specimens of prostate cancer from various cohorts of patients were analyzed. [Clin Cancer Res] The Tocopherol Transfer Protein Sensitizes Prostate Cancer Cells to Vitamin E Researchers hypothesized that over-expression of the tocopherol transfer protein, a vitamin E-binding protein that regulates tocopherol status, will sensitize prostate cancer cells to the anti-proliferative actions of the vitamin. [J Biol Chem] Embelin Suppresses Osteoclastogenesis Induced by RANKL and Tumor Cells In Vitro Through Inhibition of the NF-KappaB Cell Signaling Pathway Researchers investigated whether embelin could inhibit osteoclastogenesis-associated bone loss induced by RANKL and by tumor cells in vitro. [Mol Cancer Res] CLINICAL RESEARCH Metronomic Administration of Zoledronic Acid and Taxotere Combination in Castration Resistant Prostate Cancer Patients – Phase I ZANTE Trial Docetaxel and zoledronic acid are effective in patients with hormone resistant prostate cancer (HRPC) with bone metastases. A phase I clinical trial of metronomic administration of Zoledronic Acid and Taxotere combination (ZANTE trial) in two different sequences was conducted in HRPC. [Cancer Biol Ther] Sleep and Daily Functioning During Androgen Deprivation Therapy for Prostate Cancer This study assessed sleep in 60 prostate cancer patients taking androgen deprivation therapy with wrist actigraphy and daily diaries for 7 days. [Eur J Cancer Care] Antiangiogenic and Antitumor Activity of LP-261, A Novel Oral Tubulin Binding Agent, Alone and in Combination with Bevacizumab Here, researchers report the results of testing in multiple mouse xenograft models and angiogenesis assays, along with bioavailability studies. [Invest New Drugs]
|